Skip to content
New: 30 more Indian companies explained, from Ather and Pine Labs to IDBI Bank

Healthcare · NSE: MARKSANS · BSE: 524404

Marksans Pharma: how the business works

Marksans Pharma makes generic medicines, mostly over-the-counter products such as painkillers, for the US, UK, Europe and Australia, earning ₹2,951 crore of revenue in FY26.

Follow Marksans Pharma

Email me when Marksans Pharma's page is updated after results.

We store your email address with Kit, our email provider, which also records when you sign up and whether you open or click our emails. We send a confirmation email first. See our privacy policy.

Marksans Pharma Limited · Mumbai, Maharashtra · Founded 1992

Updated for Q2 FY27 · checked

Revenue, FY26
₹2,951 cr
Net profit, FY26
₹418 cr
Manufacturing plants (Goa, US, UK)
4
Incorporated
1992
Promoter holding, 30 Sep 2026
43.87%

For learning only. Cityfort is not a SEBI-registered adviser and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

The short version

Marksans Pharma in 5 points

  1. 1 · What it sells

    Marksans Pharma makes generic medicines, mostly over-the-counter products such as painkillers, often sold under shop chains' own brands, and its FY26 revenue was ₹2,951 crore.

    More: what it sells

  2. 2 · Who pays it

    In FY26, customers in the US and North America gave 52.0% of Marksans' revenue, Europe and the UK 34.4%, Australia and New Zealand 10.3% and other countries 3.4%.

    More: who pays it

  3. 3 · What it keeps from ₹100

    Of every ₹100 that came in during FY26, Marksans kept ₹13.8 as profit, and that ₹100 included ₹2.7 of other income, mostly currency gains, while operating profit before that income (EBITDA) was 20.4% of revenue (Cityfort calculation).

    More: what it keeps from ₹100

  4. 4 · Where the operating profit comes from

    Marksans reports one segment and gives no profit by region or product, though its presentation put over-the-counter medicines at 80.0% of FY26 revenue and pain-management products at ₹1,311 crore.

    More: where the operating profit comes from

  5. 5 · The one thing to watch

    Two unnamed customers gave ₹679.1 crore, or 23.0%, of Marksans' FY26 revenue, while in FY24 and FY25 no single customer reached 10%.

    More: the one thing to watch

Sources: From Marksans' FY24, FY25 and FY26 annual reports, its Q2 FY27 results notes and its Q2 FY27 investor presentation · checked

01Where the money goes · FY26

Where does ₹100 of Marksans Pharma's money go?

Of every ₹100 that came in (revenue plus other income), this is where it went.

Marksans Pharma · FY26

Receipt for every ₹100

Where ₹100 of Marksans Pharma's money went in FY26
Materials and goods bought for resale₹42.1
Employee costs₹13.9
Other running costs₹21.5
Depreciation and interest₹4.0
Income tax and minority holders' share₹4.7
Kept as profit₹13.8
Total₹100

Each line = amount ÷ total money in × 100. Lines may not add to exactly ₹100 because of rounding.

How this is worked out

Cityfort calculation from the FY26 annual report: each line ÷ total money in (revenue of ₹2,951 crore plus other income of ₹82.5 crore = ₹3,033 crore) × 100. Other income was ₹2.7 of each ₹100. The tax line includes ₹2.2 crore of profit belonging to Nova's minority holders.

Save this receipt as an image

Embed this receipt or the key numbers

Paste this code into a blog or website to show the card you choose, with a link back to this page.

Each week: the next company due to report results, explained in 5 points.

We'll email you once a week with what changed on Cityfort. Facts only, no tips. Unsubscribe any time.

We store your email address with Kit, our email provider, which also records when you sign up and whether you open or click our emails. We send a confirmation email first. See our privacy policy.

02The business in one line

What does Marksans Pharma do?

Shop chains and other buyers in the US, UK, Europe and Australia pay Marksans for the generic medicines it makes; materials take the biggest share, and ₹13.8 of every ₹100 that came in was left as profit in FY26.

  • In FY26 customers in the US and North America gave 52.0% of Marksans' revenue, Europe and the UK 34.4%, Australia and New Zealand 10.3% and other countries 3.4%.
  • Of every ₹100 that came in during FY26, ₹42.1 went on materials and goods bought for resale, ₹21.5 on other running costs and ₹13.9 on staff (Cityfort calculation).

03Who pays it

Who pays Marksans Pharma?

  • Buyers in the US and North America

    52%

    of revenue

    Mostly retail chains buying store-brand OTC medicines. CARE said in Oct 2025 that about 90% of FY25 US revenue was OTC and that retail chains gave nearly 80% of OTC revenue. The US and North America gave 52.0% of FY26 revenue.

  • Buyers in Europe and the UK

    34.4%

    of revenue

    Bell, Sons & Co. sells OTC medicines (450+ products) and Relonchem sells prescription generics in the UK; QliniQ (Netherlands) and ABCnow (Germany) joined in 2026. Europe and the UK gave 34.4% of FY26 revenue.

  • Buyers in Australia and New Zealand

    10.3%

    of revenue

    Nova Pharmaceuticals, 60% owned, sells OTC and branded prescription medicines. Australia and New Zealand gave 10.3% of FY26 revenue.

  • Other countries, including India

    3.4%

    of revenue

    About 10 countries in the CIS and the Middle East and North Africa. Other countries gave 3.4% of FY26 revenue.

  • Buyers in the US and North America52%
  • Buyers in Europe and the UK34.4%
  • Buyers in Australia and New Zealand10.3%
  • Other countries, including India3.4%

How spread out the customers are

Two unnamed customers each gave at least 10% of FY26 revenue, ₹679.1 crore (23.0%) together; in FY24 and FY25 no single customer reached 10%. One customer was more than 10% of trade receivables on 31 Mar 2026.

04How it makes money

How does Marksans Pharma make money?

Materials took a smaller share of each rupee of sales from FY22 to FY26, and operating profit a larger one.

Between FY22 and FY26, materials and goods bought for resale fell from 48.1% to 43.3% of revenue, while other running costs rose from 19.8% to 22.1% and staff costs moved from 14.8% to 14.3% (Cityfort calculations). EBITDA (profit before interest, tax and wear-and-tear of assets) rose from 17.4% to 20.4% of revenue. The company said its H1 FY27 gross margin of 58.8% was supported by lower-cost inventory, currency gains and product mix.

EBITDA margin (EBITDA ÷ revenue)

17.4%20.4%

FY22 to FY26

  1. Retail chains in the US and UK order medicines to sell under their own brand names.
  2. Marksans makes them in Goa, the US and the UK; management said in Feb 2026 that the newer Goa plant was running at around 50% of capacity.
  3. It files for new product licences (350+ approved by FY26) to add products to each shelf.
  4. Materials and goods bought for resale took 43.3% of FY26 revenue, against 48.1% in FY22 (Cityfort calculation).
  5. EBITDA was 20.4% of revenue in FY26 and 22.8% in Q2 FY27.
  6. Prices can fall: management described UK price erosion in Nov 2025, and Europe and UK revenue fell 1.4% in FY26.

↺ Step 6 feeds back into step 1.

05Business segments · FY26

Which businesses make up Marksans Pharma?

  • US and North America

    52%

    Revenue by customer location from the annual report's geographic note; Marksans reports one business segment, so no profit is given by region. Mostly store-brand OTC medicines; up 24.0% in FY26.

    Revenue ₹1,534 cr

  • Europe and UK

    34.4%

    OTC and prescription medicines through Bell, Sons & Co. and Relonchem; down 1.4% in FY26.

    Revenue ₹1,015 cr

  • Australia and New Zealand

    10.3%

    OTC and branded prescription medicines through Nova Pharmaceuticals (60% owned).

    Revenue ₹303 cr

  • Rest of world (incl. India)

    3.4%

    Other countries, mainly in the CIS and the Middle East; FY22 and FY23 also include a separate India line.

    Revenue ₹99.4 cr

How the mix changed

  • US and North America
  • Europe and UK
  • Australia and New Zealand
  • Rest of world (incl. India)

Revenue by segment, FY22 to FY26.

₹ crore

See the numbers
How the mix changed (₹ crore)
YearUS and North AmericaEurope and UKAustralia and New ZealandRest of world (incl. India)
FY22₹635₹609₹180₹66.9
FY23₹775₹768₹210₹100
FY24₹918₹943₹219₹97.4
FY25₹1,237₹1,030₹253₹104
FY26₹1,534₹1,015₹303₹99.4

06The numbers · Consolidated · ₹ crore

How has Marksans Pharma done?

Revenue

₹2,951 crFY26

Revenue rose every year, from ₹1,491 crore in FY22 to ₹2,951 crore in FY26, and Q2 FY27 revenue of ₹940 crore was 30.5% above Q2 FY26, including QliniQ from Q1 FY27.

₹ crore

See the numbers
Revenue (₹ crore)
PeriodRevenue (₹ cr)
FY22₹1,491
FY23₹1,852
FY24₹2,177
FY25₹2,623
FY26₹2,951
Q3 FY25₹682
Q4 FY25₹709
Q1 FY26₹620
Q2 FY26₹720
Q3 FY26₹754
Q4 FY26₹856
Q1 FY27₹841
Q2 FY27₹940

Net profit

₹418 crFY26

Net profit for Marksans' shareholders rose from ₹185 crore in FY22 to ₹418 crore in FY26, and Q2 FY27 profit of ₹141 crore was 43.8% above Q2 FY26; these figures leave out the profit of Nova's minority holders.

₹ crore

See the numbers
Net profit (₹ crore)
PeriodNet profit (₹ cr)EPS (₹)
FY22₹185₹4.51
FY23₹266₹6.41
FY24₹314₹6.92
FY25₹381₹8.40
FY26₹418₹9.22
Q3 FY25₹105₹2.31
Q4 FY25₹90.5₹2.00
Q1 FY26₹58.3₹1.29
Q2 FY26₹98.3₹2.17
Q3 FY26₹113₹2.50
Q4 FY26₹148₹3.27
Q1 FY27₹157₹3.47
Q2 FY27₹141₹3.12

Net profit for every ₹100 of revenue

₹14.2FY26

EBITDA was 20.4% of revenue in FY26 against 17.4% in FY22, and 22.8% in Q2 FY27; no year or quarter shown had exceptional items, and EBITDA leaves out other income, which included ₹50.1 crore of currency gains in FY26.

Net margin: ₹ of net profit per ₹100 of revenue

See the numbers
Net profit for every ₹100 of revenue (Net margin: ₹ of net profit per ₹100 of revenue)
YearNet marginEBITDA margin
FY2212.4%17.4%
FY2314.4%18.3%
FY2414.4%21.1%
FY2514.5%20.3%
FY2614.2%20.4%

Free cash flow

₹328 crFY26

Free cash flow (operating cash flow minus capital spending) was positive in every year from FY22 to FY26, ₹620 crore in total (Cityfort calculation), and ₹328 crore in FY26.

₹ crore · cash from operations minus spending on plants and equipment

See the numbers
Free cash flow (₹ crore · cash from operations minus spending on plants and equipment)
YearCash from operationsCapital spendingFree cash flow
FY22₹99.3₹46.3₹52.9
FY23₹237₹53.6₹184
FY24₹230₹209₹21.6
FY25₹207₹173₹33.7
FY26₹458₹131₹328
See all yearly numbers
Marksans Pharma annual financials, FY22–FY26, ₹ crore
YearRevenueEBITDANet profitEPS (₹)Operating cashCapexFree cash
FY22₹1,491₹259₹185₹4.51₹99.3₹46.3₹52.9
FY23₹1,852₹339₹266₹6.41₹237₹53.6₹184
FY24₹2,177₹459₹314₹6.92₹230₹209₹21.6
FY25 (restated)₹2,623₹533₹381₹8.40₹207₹173₹33.7
FY26₹2,951₹601₹418₹9.22₹458₹131₹328

EBITDA = profit before interest, tax and wear-and-tear of assets. Financial year runs April to March (March year end). Net profit is the share belonging to the company's owners.

07Who runs it

Who runs Marksans Pharma, and did they deliver?

  • Mark Saldanha

    Chairman and Managing Director

    Founder, the company's presentation says; CARE says he was earlier a whole-time director of Glenmark Pharmaceuticals. He held 43.80% of the shares on 30 Sep 2026. FY26 pay was ₹7.69 crore, and the group paid him ₹1.07 crore of rent.

  • Sandra Saldanha

    Whole-time Director

    A member of the promoter group, holding 0.02% of the shares on 30 Sep 2026.

  • Varddhman V. Jain

    Whole-time Director

    One of three executive directors on an eight-member board, which has four independent directors.

  • Jitendra Sharma

    Group Chief Financial Officer

    Also a director of the group's subsidiaries, CARE says.

  • Harshavardhan Panigrahi

    Company Secretary

    A key managerial person on 31 Mar 2026.

What they said, and what happened

1 delivered · 3 too early to tell

  1. Said on 6 Feb 2026

    Management said on the 6 Feb 2026 call that employee costs should come back to about 13–13.5% of revenue "maybe by the second quarter of next financial year".

    What happened

    Employee costs were ₹122 crore in Q2 FY27, 13.0% of revenue, against 14.3% in FY26 (Cityfort calculation); Q2 FY27 includes QliniQ.

    Delivered
  2. Said on 27 May 2026

    Management said on the 27 May 2026 call that FY27 revenue would grow by 15% to 20%, with the EBITDA margin about the same as the 20–21% range it was asked about.

    What happened

    H1 FY27 revenue rose 32.9% and EBITDA was 24.0% of revenue, including about ₹84 crore of QliniQ revenue; the company put organic growth at about 27%. FY27 ends on 31 Mar 2027.

    Too early to tell
  3. Said on 27 May 2026

    Management said on the 27 May 2026 call: "our target is still there for INR4,000 crores in the next 2 years", and repeated the target on 13 Aug 2026.

    What happened

    FY26 revenue was ₹2,951 crore and H1 FY27 revenue ₹1,781 crore.

    Too early to tell
  4. Said on 13 Aug 2026

    Management said on the 13 Aug 2026 call that it expected QliniQ to bring in about ₹150–175 crore of revenue in FY27, and Germany to start bringing in revenue, perhaps early in the third quarter.

    What happened

    The company put QliniQ's H1 FY27 revenue at about ₹84 crore. ABCnow, in Germany, has been a subsidiary since 1 Jul 2026.

    Too early to tell

08What could go wrong

What could go wrong for Marksans Pharma?

  • Concentration

    Two customers give almost a quarter of revenue

    Two unnamed customers gave ₹679.1 crore, 23.0% of FY26 revenue; in FY24 and FY25 no single customer reached 10%. CARE said retail chains gave nearly 80% of US OTC revenue in FY25.

    Watch The customer note in the FY27 annual report.

  • Pricing

    Falling prices for generic medicines

    Management said on the 14 Nov 2025 call that the UK had seen tremendous price erosion, and Europe and UK revenue fell 1.4% in FY26. The company said US prescription price erosion stayed in single digits in Q2 FY27.

    Watch Europe and UK revenue each quarter, with and without QliniQ.

  • Concentration

    One therapy gives the biggest share

    Pain-management products sold ₹1,311 crore, 44.4% of FY26 revenue (Cityfort calculation from the company's presentation). CARE called this a segment concentration risk in Oct 2025.

    Watch The therapy split in the company's presentations.

  • Regulation

    Plant inspections by foreign regulators

    Sales in the US, UK and Australia depend on plants their regulators approve. A subsidiary received a US FDA observation in Apr 2025, closed in Jun 2025, CARE said; the second Goa plant's Nov 2025 inspection ended with zero observations.

    Watch US FDA, UK MHRA and Australian TGA inspection results filed with the exchanges.

  • Regulation

    US trade rules

    The US and North America gave 52.0% of FY26 revenue. CARE said in Oct 2025 that a 100% US tariff on imported branded or patented medicines did not apply to generics, Marksans' main business, and that tariff developments would remain a key monitorable.

    Watch US tariff rules for generic medicines and US revenue each quarter.

  • Currency

    Currency moves

    The Indian company exported 100% of its FY26 turnover, and other income included ₹50.1 crore of currency gains in FY26. CARE said the company's exposure is mainly in US dollars and euros.

    Watch Currency gains or losses in the notes to each quarter's results.

  • Execution

    Fitting in new acquisitions

    Goodwill rose from ₹45.3 crore on 31 Mar 2026 to ₹103 crore on 30 Sep 2026 after the QliniQ and ABCnow purchases, whose purchase price allocations are still provisional.

    Watch Final purchase price allocation and QliniQ's revenue against management's ₹150–175 crore expectation for FY27.

09Supporters and critics

What do supporters and critics point to?

Facts each side points to. We don't say which side is right.

What supporters point to

  • Revenue rose every year from FY22 to FY26, from ₹1,491 crore to ₹2,951 crore, and profit for shareholders from ₹185 crore to ₹418 crore.
  • Free cash flow was positive in each of the five years, ₹620 crore in total, and borrowings were ₹29.0 crore against ₹1,124 crore of cash and investments on 30 Sep 2026.
  • No promoter shares were pledged in any of the 12 quarters from Dec 2023 to Sep 2026.
  • The second Goa plant's US FDA inspection in Nov 2025 ended with zero Form 483 observations.
  • Without QliniQ, the company put Q2 FY27 revenue growth at about 25%.

What critics point to

  • Two unnamed customers gave 23.0% of FY26 revenue, while no single customer reached 10% in FY24 or FY25.
  • CARE said about 45% of revenue came from pain management and called the OTC segment highly competitive and price-sensitive.
  • Europe and UK revenue fell 1.4% in FY26, and management described UK price erosion on the Nov 2025 call.
  • Lease liabilities of ₹314 crore on 31 Mar 2026 were more than ten times borrowings of ₹29.6 crore.
  • Other income in FY26 included ₹50.1 crore of currency gains, equal to 8.9% of profit before tax (Cityfort calculation).

10What to watch next

What should you watch next at Marksans Pharma?

Next event

Q3 FY27 results

Date not announced yet.

  • Customer concentration

    Two customers gave 23.0% of FY26 revenue; the FY27 annual report will show whether that share changed.

  • Growth without acquisitions

    The company put Q2 FY27 revenue growth without QliniQ at about 25%; ABCnow has been included since 1 Jul 2026.

  • The ₹4,000 crore target

    Management said on 27 May 2026 that its target was ₹4,000 crore of revenue in the next 2 years; FY26 revenue was ₹2,951 crore and H1 FY27 revenue ₹1,781 crore.

11Key facts

Key facts about Marksans Pharma

What does Marksans Pharma do?
Marksans Pharma Ltd, a Mumbai company incorporated in 1992, makes generic medicines such as painkillers and cough-and-cold products at four plants, two in Goa and one each in the US and the UK. Marksans Pharma sells them mainly in the US, the UK, Europe and Australia, and its FY26 revenue was ₹2,951 crore.
How does Marksans Pharma make money?
Marksans Pharma earns most of its money from medicines sold without a prescription: its presentation put over-the-counter (OTC) products at 80.0% of FY26 revenue and prescription medicines at 20.0%. Pain-management products sold ₹1,311 crore in FY26, 44.4% of Marksans Pharma's revenue (Cityfort calculation from the company's presentation).
Who are Marksans Pharma's customers?
Marksans Pharma makes medicines that retail chains sell under their own brands; CARE Ratings said in Oct 2025 that retail chains gave nearly 80% of Marksans Pharma's US OTC revenue in FY25. In FY26 two unnamed customers together gave ₹679 crore, or 23.0% of Marksans Pharma's revenue.
How big is Marksans Pharma?
In FY26 Marksans Pharma earned ₹2,951 crore of revenue and ₹418 crore of net profit for its shareholders, against ₹2,623 crore and ₹381 crore in FY25. The FY26 annual report says the Marksans Pharma group has more than 2,000 employees.
Who owns Marksans Pharma?
On 30 Sep 2026 the promoter group held 43.87% of Marksans Pharma, almost all of it (43.80%) in founder Mark Saldanha's name, with no shares pledged. OrbiMed Asia IV Mauritius held 8.62%, foreign portfolio investors 10.44%, Indian institutions 5.54% and other shareholders 31.53%.
How did Marksans Pharma do in Q2 FY27?
In Q2 FY27 (Jul–Sep 2026) Marksans Pharma's revenue was ₹940 crore, up 30.5% from ₹720 crore in Q2 FY26, and net profit for shareholders was ₹141 crore, up 43.8% from ₹98.3 crore. Marksans Pharma said QliniQ, a Dutch company it bought in 2026, added about ₹40 crore of the quarter's revenue.
Does Marksans Pharma have debt?
Marksans Pharma had ₹29.0 crore of borrowings and ₹1,124 crore of cash, bank balances and current investments on 30 Sep 2026. Marksans Pharma's lease liabilities, shown separately from borrowings, were ₹314 crore on 31 Mar 2026.
What dividend does Marksans Pharma pay?
Marksans Pharma's board recommended a final dividend of ₹0.90 a share for FY26, against ₹0.80 for FY25 and ₹0.60 for FY24. The FY26 dividend comes to ₹40.8 crore.
What did Marksans Pharma buy in 2026?
Marksans Pharma bought QliniQ B.V. of the Netherlands for EUR 7.50 million, a subsidiary from 1 Apr 2026, and ABCnow GmbH of Germany, a subsidiary from 1 Jul 2026, for EUR 1.10 million according to the Q2 FY27 results.

Terms on this page

Each explains the term in plain English, with the same number from other companies on Cityfort.

Go deeper

More detail from the same filings. Open any section.

12What it sells

12What it sells

What does Marksans Pharma sell?

Marksans makes generic medicines: copies of medicines whose patents have ended, as tablets, capsules and soft-gel capsules. Most are sold without a prescription, often under a shop chain's own brand. The rest are prescription medicines, sold mainly in the UK, Australia and the US.
  • Over-the-counter (OTC) medicines

    Painkillers, cough-and-cold, digestive and allergy products that people buy without a prescription. The company's presentation put OTC at 80.0% of FY26 revenue. It says about 85% of OTC revenue came from store brands (shop chains' own labels) and the rest from its own labels, an approximate split.

  • Prescription generics

    Medicines a doctor prescribes, 20.0% of FY26 revenue. Relonchem holds 175+ UK marketing authorisations (licences to sell a medicine), and Nova Pharmaceuticals launched 11 branded prescription medicines in Australia and New Zealand in FY26.

  • Pain-management products

    The largest therapy group: ₹1,311 crore in FY26, 44.4% of revenue (Cityfort calculation from the company's presentation). CARE Ratings put pain management at about 45% of revenue and cough and cold at 13% in its Oct 2025 report.

What it does

  • Does: Makes medicines at four plants: two in Verna, Goa, one in the US (Time-Cap Labs) and one in the UK
  • Does: Holds 350+ approved product licences (US ANDAs and marketing authorisations elsewhere), with 30+ awaiting approval, the FY26 annual report says
  • Does: Exports everything the Indian company makes: 100% of the standalone FY26 turnover went abroad, to 50+ countries

What it does not do

  • Does not: Does not sell much in India: India sits in 'rest of world', which with other countries gave 3.4% of FY26 revenue
  • Does not: Does not name its two largest customers
  • Does not: Does not report profit by region or product: it reports one segment, pharmaceuticals
13How the money flows

13How the money flows · FY26

How does money flow through Marksans Pharma?

Money in

  • Revenue from operations₹2,951 cr
  • Other income (including ₹50.1 crore of currency gains)₹82.5 cr

The company

Marksans Pharma

₹3,033 cr came in

Money out

  • Materials and goods bought for resale₹1,277 cr
  • Employee costs₹421 cr
  • Other running costs₹652 cr
  • Depreciation and interest₹123 cr
  • Income tax₹141 cr
  • Profit belonging to Nova's minority holders₹2.2 cr
  • Net profit₹418 cr
  1. In FY26 Marksans sold ₹2,951 crore of medicines and earned ₹82.5 crore of other income, including ₹50.1 crore of currency gains.
  2. Materials and goods bought for resale took ₹1,277 crore, the biggest cost.
  3. Other running costs took ₹652 crore and employees ₹421 crore.
  4. Depreciation and interest took ₹123 crore, income tax ₹141 crore and Nova's minority holders ₹2.2 crore.
  5. What was left was ₹418 crore of net profit for Marksans' shareholders.
14What it needs to run

14What it needs to run

What does Marksans Pharma need to run?

  • Plants

    Four manufacturing units: two in Verna, Goa, one in the US and one in the UK. The Indian plants can make 14 billion tablets and 2.4 billion soft-gel and hard capsules a year.

  • Regulator approvals

    Buyers in the US, UK and Australia need plants their regulators approve. The second Goa plant, bought from Tevapharm India in FY23, Marksans announced on 20 Mar 2025 that the plant had won Australian TGA approval, and a US FDA inspection on 3–7 Nov 2025 ended with zero Form 483 observations (no inspector findings recorded).

  • Product licences

    Each medicine needs a licence in each country. The FY26 annual report lists 350+ approved licences, 30+ awaiting approval and 200+ products in development; R&D spending was ₹89.0 crore in FY26.

  • People

    More than 2,000 employees across the group; the Indian company had 1,685 permanent employees on 31 Mar 2026.

  • Stock and credit to customers

    Inventories were ₹972 crore and trade receivables ₹645 crore on 31 Mar 2026. The company put its working-capital cycle at about 138 days in FY26 and about 128 days in H1 FY27.

15Where growth could come from

15Where growth could come from

Where could Marksans Pharma's growth come from?

Management said on the 27 May 2026 call that it expected FY27 revenue to grow by 15% to 20%, with the EBITDA margin about the same as the 20–21% range it was asked about, and that "our target is still there for INR4,000 crores in the next 2 years". On the 13 Aug 2026 call management said it would stick with that plan.
Management statement, 27 May 2026. Reported as a statement, not our forecast.
  • US store brands

    Working

    ₹1,534 crore, FY26 (up 24.0%)

    US and North America revenue rose from ₹1,237 crore in FY25 to ₹1,534 crore in FY26. The company put Q2 FY27 at ₹421 crore, up 8.7%, and says it aims to double US store-brand OTC revenue, without giving a date.

    Status: Working, on track against what the company said.

  • UK and Europe

    Mixed

    ₹405 crore, Q2 FY27 (company)

    Europe and UK revenue fell 1.4% in FY26 to ₹1,015 crore. The company put Q2 FY27 at ₹405 crore, up 64.9%, or 48.6% without QliniQ, and said the UK market had stabilised after a flat FY26.

    Status: Mixed, partly on track.

  • European acquisitions

    New

    About ₹84 crore, H1 FY27 (QliniQ, company)

    QliniQ (Netherlands) is a subsidiary from 1 Apr 2026 and ABCnow (Germany) from 1 Jul 2026. Management said on 13 Aug 2026 that it expected QliniQ to bring in about ₹150–175 crore of revenue in FY27.

    Status: New, recently announced.

  • Australia and New Zealand

    Working

    ₹303 crore, FY26 (₹180 crore in FY22)

    Nova (60% owned) launched 11 branded prescription medicines in FY26. The company put Q2 FY27 revenue in the region at ₹101 crore, up 64.0%.

    Status: Working, on track against what the company said.

  • Second Goa plant

    Working

    Around 50% used, Feb 2026 (management)

    Bought from Tevapharm India in FY23. CARE said it brought in over ₹300 crore of revenue in FY25, and its US FDA inspection in Nov 2025 ended with zero observations.

    Status: Working, on track against what the company said.

Status compares progress with what the company itself said it would do: Working = on track against what the company said; Mixed = partly on track; Behind = behind the company's own plan; New = recently announced; Early = too early to judge.

16Financial strength and debt

16Financial strength · 30 Sep 2026

How much debt does Marksans Pharma have?

On 30 Sep 2026 cash, bank balances and current investments of ₹1,124 crore were ₹1,095 crore more than borrowings of ₹29.0 crore, the net cash figure the company's Q2 FY27 presentation also gives.
  • Total debt₹29 cr
  • Cash and investments₹1,124 cr
  • Net cash (cash minus debt)₹1,095 cr
  • Net worth (shareholders' money)₹3,332 cr
Debt to equity
0.01×
₹ of debt for every ₹1 of shareholders' money
  • Borrowings are all short-term and were between ₹23 crore and ₹42 crore at every year end from Mar 2022 to Mar 2026.
  • Lease liabilities are shown separately from borrowings: ₹314 crore on 31 Mar 2026, against ₹69.5 crore on 31 Mar 2022. Counting them, cash and investments exceeded borrowings and leases by ₹646 crore on 31 Mar 2026 (Cityfort calculation from the FY26 annual report).
  • The FY26 annual report shows no contingent liabilities on 31 Mar 2026 or 31 Mar 2025.
  • Inventories were ₹996 crore and trade receivables ₹757 crore on 30 Sep 2026.
  • CARE Ratings upgraded the long-term bank facilities to CARE AA-; Stable on 6 Oct 2025, and India Ratings revised its outlook to Positive on 9 Jun 2026.
  • Debt to equity = borrowings ÷ shareholders' equity of ₹3,332 crore (Cityfort calculation).
17Who owns it

17Who owns it · Q2 FY27

Who owns Marksans Pharma?

  • Promoters (founders or parent company)43.9%
  • Foreign institutions (FII)10.4%
  • Indian institutions (DII)5.5%
  • Public and others40.2%

Promoter pledge

No promoter shares were pledged in Q2 FY27.

How ownership changed
Marksans Pharma shareholding by quarter, %
QuarterPromotersFIIDIIPublicOthers†Pledged*
Q3 FY2443.9%4.7%4.8%35.8%10.9%0.0%
Q4 FY2443.9%4.7%5.2%35.4%10.9%0.0%
Q1 FY2543.9%7.7%3.8%33.8%10.9%0.0%
Q2 FY2543.9%10.4%4.1%30.7%10.9%0.0%
Q3 FY2543.9%11.1%4.3%29.9%10.9%0.0%
Q4 FY2543.9%11.3%4.6%29.4%10.9%0.0%
Q1 FY2643.9%11.3%5.5%30.7%8.6%0.0%
Q2 FY2643.9%8.3%5.3%33.9%8.6%0.0%
Q3 FY2643.9%8.1%5.9%33.5%8.6%0.0%
Q4 FY2643.9%8.1%6.6%32.8%8.6%0.0%
Q1 FY2743.9%8.9%6.2%32.5%8.6%0.0%
Q2 FY2743.9%10.4%5.5%31.5%8.6%0.0%

* Pledged = share of the promoters' own holding reported as pledged. In older filings this can include shares “otherwise encumbered”; the governance flags say when.

† Others = OrbiMed Asia IV Mauritius (foreign direct investment).

18What it does with profit

18What it does with profit

What does Marksans Pharma do with its profit?

Payout = dividend per share ÷ earnings per share (Cityfort calculation). The FY26 final dividend of ₹0.90 a share comes to ₹40.8 crore. In Jan 2023 Marksans issued 50,324,324 shares at ₹74 each on conversion of warrants, 49,324,324 of them to OrbiMed Asia IV Mauritius and 1,000,000 to Mark Saldanha, raising ₹372.4 crore in total. In FY23 it also bought back shares at up to ₹60 each (₹49.60 on average), 1.58% of its shares, for ₹40.2 crore including tax.

Dividend per share

₹0.90FY26

Dividend paid for each share, by financial year.

₹ per share

See the numbers
Dividend per share (₹ per share)
YearDividend per shareShare of profit paid out
FY24₹0.608.7%
FY25₹0.809.5%
FY26₹0.909.8%

No buybacks or fund raises in the period covered.

19Governance signals

19Governance signals

What do Marksans Pharma's governance filings show?

Auditor
M S K A & Associates LLP, since 2022
Auditor changes
31 May 2022: Bhuta Shah & Co. LLP → M S K A & Associates (Bhuta Shah & Co. LLP resigned, citing preoccupation with other assignments and the voluminous audit work involved; the board appointed M S K A & Associates on 30 May 2022 to fill the casual vacancy, the FY22 annual report says.)
Audit qualifications
None reported
Related-party dealings
In FY26 the group paid key managers ₹13.3 crore of remuneration, ₹7.69 crore of it to Mark Saldanha, and paid him ₹1.07 crore of rent, according to the consolidated related-party note of the FY26 annual report.
Credit rating
India Ratings and Research IND AA-/Positive/IND A1+ on ₹195.75 crore of bank loan facilities (outlook revised to Positive from Stable) (outlook Positive), 9 Jun 2026

A credit rating describes the company's ability to repay debt. It is not a rating of the share.

Flags to know about

  • auditor · 31 May 2022

    Previous auditor resigned in 2022

    Bhuta Shah & Co. LLP resigned as statutory auditor with effect from 31 May 2022, citing preoccupation with other assignments and the voluminous audit work involved. The board appointed M S K A & Associates the day before, and the FY22 AGM notice sought a five-year term for it.

  • regulatory · 6 Oct 2025

    US FDA observation at a subsidiary, closed

    CARE said that in Apr 2025 one of Marksans' subsidiaries received an inspectional observation from the US FDA on routine current good manufacturing practices, and that the FDA issued an Establishment Inspection Report closing the inspection in Jun 2025.

  • disclosure · 4 Aug 2026

    Largest customers not named

    The FY26 annual report says two customers gave ₹679.1 crore, 23.0% of revenue, but does not name them, and Marksans reports a single segment with no profit by region or product.

20What the market paid

20What the market paid · price as of 11 Nov 2026

What did the market pay for Marksans Pharma on 11 Nov 2026?

Price as of 11 Nov 2026 (shown for education; prices change daily).

Price as of 11 Nov 2026: ₹306.55, the NSE closing price. Market value = price × 453,163,746 shares (30 Sep 2026 shareholding pattern) = ₹13,892 crore (Cityfort calculation from the NSE closing price and the shareholding pattern); 56,250 more shares were allotted under the ESOP scheme on 4 Nov 2026. P/E (price ÷ earnings) = market value ÷ profit for shareholders of the last four quarters (Q3 FY26 to Q2 FY27, ₹560 crore) = 24.8; on FY26 profit it is 33.2. P/B = market value ÷ shareholders' equity on 30 Sep 2026 (₹3,332 crore) = 4.2. Dividend yield = FY26 dividend of ₹0.90 ÷ price = 0.29%.

Share price
₹306.55
Market value (market cap)
₹13,892 cr
P/E
24.8×
P/B
4.2×

Source: NSE historical price data MARKSANS (EQ), 2–11 Nov 2026; close ₹306.55 on 11 Nov 2026; Shareholding pattern Sep-26 (XBRL); Allotment of 56,250 shares under ESOP Scheme 2024 and 5 more

21How it got here

21How it got here

How did Marksans Pharma get here?

  1. 1992

    Milestone

    Incorporated

    Marksans Pharma Ltd was incorporated in 1992, its FY26 annual report says.

  2. 2003

    Business-model change

    Separated from Glenmark

    The FY26 annual report's timeline says the company began as a wholly owned subsidiary of Glenmark Pharmaceuticals, was spun off in 2003 as Glenmark Laboratories Ltd and renamed Marksans Pharma Ltd.

  3. 2005

    Milestone

    Australia: Nova Pharmaceuticals

    Marksans bought 60% of Nova Pharmaceuticals Australasia, its business in Australia and New Zealand.

  4. 2007

    Business-model change

    UK: Bell, Sons & Co.

    Marksans bought Bell, Sons & Co. (Druggists), a UK OTC medicine maker, and added Relonchem, a UK prescription generics company, in 2008.

  5. 2015

    Business-model change

    US: Time-Cap Labs

    Marksans bought Time-Cap Laboratories, a US maker of OTC medicines; the US and North America became its largest region, 52.0% of FY26 revenue.

  6. 2023

    Milestone

    Second Goa plant and ₹372 crore raised

    Marksans bought a plant in Goa from Tevapharm India and raised ₹372.40 crore when warrants issued to OrbiMed and the promoters were converted into shares.

  7. 2025

    Milestone

    US FDA inspection with zero observations

    The US FDA inspected the second Goa plant on 3–7 Nov 2025 and closed with zero Form 483 observations.

  8. 2026

    Business-model change

    Into mainland Europe

    Marksans bought QliniQ B.V. in the Netherlands (a subsidiary from 1 Apr 2026) and ABCnow GmbH in Germany (from 1 Jul 2026).

22Sources and changes

Where every number on this page comes from

Sources (42 documents)
  1. S1Annual Report 2025-26 (FY26), incl. BRSR · Marksans Pharma Ltd (company IR site) · Tier 1: company or exchange filing · 4 Aug 2026
  2. S2Annual Report 2024-25 (FY25) · Marksans Pharma Ltd (company IR site) · Tier 1: company or exchange filing · 16 Jul 2025
  3. S3Annual Report 2023-24 (FY24) · Marksans Pharma Ltd (company IR site) · Tier 1: company or exchange filing · 31 Aug 2024
  4. S4Annual Report 2022-23 (FY23) · Marksans Pharma Ltd (company IR site) · Tier 1: company or exchange filing · 8 Aug 2023
  5. S5Annual Report 2021-22 (FY22) · Marksans Pharma Ltd (company IR site) · Tier 1: company or exchange filing · 4 Aug 2022
  6. S6Consolidated results XBRL Q2 FY27, incl. half-year balance sheet and cash flow (integrated filing) · NSE (XBRL) · Tier 1: company or exchange filing · 4 Nov 2026
  7. S7Consolidated results XBRL Q1 FY27 (integrated filing) · NSE (XBRL) · Tier 1: company or exchange filing · 12 Aug 2026
  8. S8Consolidated results XBRL Q4 FY26 and FY26, incl. balance sheet and cash flow (integrated filing) · NSE (XBRL) · Tier 1: company or exchange filing · 26 May 2026
  9. S9Consolidated results XBRL Q3 FY26 (integrated filing) · NSE (XBRL) · Tier 1: company or exchange filing · 5 Feb 2026
  10. S10Consolidated results XBRL Q2 FY26, incl. half-year balance sheet and cash flow (integrated filing) · NSE (XBRL) · Tier 1: company or exchange filing · 13 Nov 2025
  11. S11Consolidated results XBRL Q1 FY26 (integrated filing) · NSE (XBRL) · Tier 1: company or exchange filing · 12 Aug 2025
  12. S13Consolidated results XBRL Q3 FY25 and 9M FY25 · NSE (XBRL) · Tier 1: company or exchange filing · 11 Feb 2025
  13. S14Consolidated results XBRL Q4 FY24 and FY24, incl. balance sheet and cash flow · NSE (XBRL) · Tier 1: company or exchange filing · 30 May 2024
  14. S15Consolidated results XBRL Q4 FY23 and FY23, incl. balance sheet and cash flow · NSE (XBRL) · Tier 1: company or exchange filing · 31 May 2023
  15. S16Outcome of board meeting: unaudited results Q2 FY27 (standalone and consolidated) · Marksans Pharma Ltd (company IR site) · Tier 1: company or exchange filing · 4 Nov 2026
  16. S17Earnings presentation Q2 & H1 FY27 · Marksans Pharma Ltd (company IR site) · Tier 1: company or exchange filing · 4 Nov 2026
  17. S19Earnings call transcript Q1 FY27 (call 13 Aug 2026) · Marksans Pharma Ltd (company IR site) · Tier 1: company or exchange filing · 20 Aug 2026
  18. S20Earnings call transcript Q4 FY26 (call 27 May 2026) · Marksans Pharma Ltd (company IR site) · Tier 1: company or exchange filing · 3 Jun 2026
  19. S21Earnings call transcript Q3 FY26 (call 6 Feb 2026) · Marksans Pharma Ltd (company IR site) · Tier 1: company or exchange filing · 12 Feb 2026
  20. S22Earnings call transcript Q2 FY26 (call 14 Nov 2025) · Marksans Pharma Ltd (company IR site) · Tier 1: company or exchange filing · 21 Nov 2025
  21. S23Shareholding pattern Dec-23 (XBRL) · NSE (XBRL) · Tier 1: company or exchange filing · 17 Jan 2024
  22. S24Shareholding pattern Mar-24 (XBRL) · NSE (XBRL) · Tier 1: company or exchange filing · 15 Apr 2024
  23. S25Shareholding pattern Jun-24 (XBRL) · NSE (XBRL) · Tier 1: company or exchange filing · 12 Jul 2024
  24. S26Shareholding pattern Sep-24 (XBRL) · NSE (XBRL) · Tier 1: company or exchange filing · 17 Oct 2024
  25. S27Shareholding pattern Dec-24 (XBRL) · NSE (XBRL) · Tier 1: company or exchange filing · 13 Jan 2025
  26. S28Shareholding pattern Mar-25 (XBRL) · NSE (XBRL) · Tier 1: company or exchange filing · 11 Apr 2025
  27. S29Shareholding pattern Jun-25 (XBRL) · NSE (XBRL) · Tier 1: company or exchange filing · 18 Jul 2025
  28. S30Shareholding pattern Sep-25 (XBRL) · NSE (XBRL) · Tier 1: company or exchange filing · 17 Oct 2025
  29. S31Shareholding pattern Dec-25 (XBRL); revised file of 19 May 2026 · NSE (XBRL) · Tier 1: company or exchange filing · 13 Jan 2026
  30. S32Shareholding pattern Mar-26 (XBRL) · NSE (XBRL) · Tier 1: company or exchange filing · 10 Apr 2026
  31. S33Shareholding pattern Jun-26 (XBRL) · NSE (XBRL) · Tier 1: company or exchange filing · 20 Jul 2026
  32. S34Shareholding pattern Sep-26 (XBRL) · NSE (XBRL) · Tier 1: company or exchange filing · 15 Oct 2026
  33. S35CARE Ratings: upgrade to CARE AA-; Stable / CARE A1+ (press release attached to company intimation) · Marksans Pharma Ltd (NSE filing) · Tier 2: rating agency or regulator · 8 Oct 2025
  34. S36Intimation: India Ratings outlook revised to Positive, IND AA-/IND A1+ affirmed · Marksans Pharma Ltd (NSE filing) · Tier 1: company or exchange filing · 9 Jun 2026
  35. S37Press release and Reg. 30 disclosure: agreement to acquire QliniQ B.V. · Marksans Pharma Ltd (NSE filing) · Tier 1: company or exchange filing · 1 Jun 2026
  36. S40Completion of ABCnow GmbH acquisition · Marksans Pharma Ltd (NSE filing) · Tier 1: company or exchange filing · 20 Jul 2026
  37. S41US FDA cGMP inspection at 2nd Goa facility (Verna) closed with zero Form 483 observations · Marksans Pharma Ltd (NSE filing) · Tier 1: company or exchange filing · 10 Nov 2025
  38. S42Australian TGA approval for Verna (Goa) facility · Marksans Pharma Ltd (NSE filing) · Tier 1: company or exchange filing · 20 Mar 2025
  39. S43Allotment of 56,250 shares under ESOP Scheme 2024 · Marksans Pharma Ltd (NSE filing) · Tier 1: company or exchange filing · 4 Nov 2026
  40. S44Outcome of board meeting 26 May 2026: audited FY26 results and final dividend ₹0.90 a share · Marksans Pharma Ltd (NSE filing) · Tier 1: company or exchange filing · 26 May 2026
  41. S46NSE historical price data MARKSANS (EQ), 2–11 Nov 2026; close ₹306.55 on 11 Nov 2026 · NSE · Tier 1: company or exchange filing · 11 Nov 2026
  42. S49Outcome of board meeting 19 May 2025: audited results Q4 FY25 and FY25 (standalone and consolidated; scanned) · Marksans Pharma Ltd (company IR site) · Tier 1: company or exchange filing · 19 May 2025
Changes to this page (v1 · 12 Nov 2026)
  1. v1 · 12 Nov 2026First version. (first version)

Numbers come only from tier 1 and tier 2 sources. Read how we research.

Disclaimer

For learning only. Cityfort is not a SEBI-registered adviser and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

Investing in securities involves risk, including loss of capital. Before making any investment decision, do your own research and consider consulting a SEBI-registered investment adviser.

Cityfort, its owners and contributors may or may not hold securities of companies covered. Content is not an offer or solicitation to buy or sell any security.

Read the full disclaimer

Cityfort publishes educational content that explains how listed companies work. Cityfort is not registered with the Securities and Exchange Board of India (SEBI) as an Investment Adviser or Research Analyst and does not provide investment advice, recommendations, ratings, price targets or any opinion on whether to buy, sell or hold any security.

All information is taken from publicly available sources, mainly company filings on BSE and NSE, which are listed on each page with dates. We work to keep it accurate and correct errors publicly, but we do not guarantee that it is complete, accurate or up to date. Any market price or price-based ratio shown is dated, may be out of date by the time you read it, and is included only to explain concepts.

Statements by company management are reported as statements, with their date and source; they are not our forecasts.